Fennec Pharmaceuticals Hits Day High with 9.75% Surge in Stock Price

Fennec Pharmaceuticals, Inc. has experienced a significant uptick in its stock performance, gaining 9.75% on August 26, 2026. The stock reached an intraday high of CAD 17.00, reflecting a strong day for the small-cap company within the Pharmaceuticals & Biotechnology sector. Over the past month, Fennec has shown impressive growth, with a 19.55% increase, outperforming the S&P/TSX 60, which rose by only 3.49% during the same period. Year-to-date, the company has achieved a remarkable 60.38% gain, significantly surpassing the S&P/TSX 60's 16.02% performance. Fennec's financial metrics indicate a robust position, with net sales reaching CAD 20.72 million, marking a 65.05% increase. The company also reported a decrease in raw material costs by 0.52% year-over-year, contributing to its positive financial outlook. Additionally, Fennec holds a substantial cash and equivalents balance of CAD 106.5 million, providing a solid foundation for future operations. With high institutional holdings at 64.97%, Fennec Pharmaceuticals continues to demonstrate its potential in the competitive pharmaceutical landscape.